Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla Ltd: More Excitement in Store - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Apr 26, 2001

    Cipla Ltd: More Excitement in Store

    The year goneby was a landmark year for pharma major Cipla, as its sales crossed the crucial Rs 10,000 m mark. Bouyed by increasing export presence the company recorded 38% rise in sales. Operating margins inched up further to a record 20.6%, up by 70 basis points. Cipla lauched more than 100 products in the last year including a wide range in therapeutic segments.

    (Rs m) FY00 FY01 Change
    Sales 7,597.5 10,476.5 37.9%
    Other Income 357.4 396.0 10.8%
    Expenditure 6,083.4 8,319.2 36.8%
    Operating Profit (EBDIT) 1,514.1 2,157.3 42.5%
    Operating Profit Margin (%) 19.9% 20.6%  
    Interest 11.4 9.1 -20.2%
    Depreciation 133.4 155.0 16.2%
    Profit before Tax 1,726.7 2,389.2 38.4%
    Other Adjustments - -  
    Tax 396.0 605.0 52.8%
    Profit after Tax/(Loss) 1,330.7 1,784.2 34.1%
    Net profit margin (%) 17.5% 17.0%  
    No. of Shares (eoy) (m) 60.0 60.0  
    Diluted Earnings per share 22.2 29.7  
    P/E (at current price)   37  

    In a related major development all the major MNC's withdrew patent litigations against the south African government for supply of Anti-AIDS drug which has come as a blessing in disguise for the company. The company's manufacturing facility is capable of catering to more than 0.1 million AIDS patients.

    The company's strategy of identifying and exploring new niche therapeutic segments to offer superior products at competitive prices seems to be paying off. The company recently launched CFC-free anti-asthma inhalers which is expected to find a huge export market. It has also ramped its research activities in its key anti-asthma therapeutic segment. Besides, with several exclusive tie-ups for generic supply and commencement of Omeprazole plant the company is all set to tap the vast US generic market.

    Thus there seems to be lot of excitement in store for the company in the coming months. At the current market price of Rs1,090, the stock is trading at a P/e of 37 times its FY01 earnings.



    Equitymaster requests your view! Post a comment on "Cipla Ltd: More Excitement in Store". Click here!


    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 22, 2017 10:01 AM



    Detailed Financial Information With Charts